37 results on '"Hajduczki, Agnes"'
Search Results
2. SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activity
Catalog
Books, media, physical & digital resources
3. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial
4. Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain
5. Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity
6. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques
7. Contemporary HIV-1 consensus Env with AI-assisted redesigned hypervariable loops promote antibody binding
8. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial
9. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
10. Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations
11. Production and Characterization of SIV-Specific CAR/CXCR5 T Cells
12. Bispecific chimeric antigen receptors targeting the CD4 binding site and high-mannose Glycans of gp120 optimized for anti–human immunodeficiency virus potency and breadth with minimal immunogenicity
13. Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity
14. Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques
15. Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN
16. A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model
17. A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates
18. 564. SARS-CoV-2 Ferritin Nanoparticle Vaccines Elicit Broad SARS Coronavirus Immunogenicity
19. A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge
20. A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters
21. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
22. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques
23. Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates
24. A Trispecific Anti-HIV Chimeric Antigen Receptor Containing the CCR5 N-Terminal Region
25. A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein
26. Chimeric antigen receptors against HIV: Bispecific CD4-based designs for enhanced breadth/potency and minimal immunogenicity
27. Simian Immunodeficiency Virus (SIV)-Specific Chimeric Antigen Receptor-T Cells Engineered to Target B Cell Follicles and Suppress SIV Replication
28. Developing soluble mimetics of the chemokine receptor CCR5 for the study of HIV Env/receptor interactions (CCR6P.216)
29. Phage display of functional, full-length human and viral membrane proteins
30. In Vitro Evolution of Ligands to the Membrane Protein Caveolin
31. Solubilization of a Membrane Protein by Combinatorial Supercharging
32. Production and Characterization of SIV-Specific CAR/CXCR5 T Cells.
33. A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters.
34. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.
35. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques.
36. Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates.
37. A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein.
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.